CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Planned sale President and CEO sold 9,000 shares at $11.99 ($107,910)
- 144 Insider Sale of Securities
- 4 Grant or award EVP, Chief Medical Officer acquired 199,822 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale VP, Chief Accounting Officer sold 1,864 shares at $12.43 ($23,170)
- 144 Insider Sale of Securities
- 8-K Event Regulation FD disclosure · Other events
- 8-K Event Material agreement · New debt or obligation · Regulation FD disclosure
- 4 Planned sale President and CEO sold 22,675 shares at an average $12.65 ($286,819)
- 144 Insider Sale of Securities
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Open-market sale EVP, Chief Financial Officer sold 8,111 shares at $11.25 ($91,249)
- 4 Open-market sale VP, Chief Accounting Officer sold 2,641 shares at $16.78 ($44,316)
- 4 Planned sale EVP, Chief Financial Officer sold 4,677 shares at $18.00 ($84,186)
- 144 Insider Sale of Securities
Page 1 of 37 · 724 filings